Eltrombopag

Base Information

• Chemical Name: Eltrombopag
• CAS No.: 496775-61-2
• Molecular Formula: C25H22N4O4
• Molecular Weight: 442.47
• Hs Code.: 2933990090
• Mol file: 496775-61-2.mol

Synonyms:Promacta;Revolade;3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid;

Chemical Property of Eltrombopag

Chemical Property:

• Appearance/Colour: Orange to red solid
• Melting Point: 242-244 °C
• Refractive Index: 1.666
• Boiling Point: 656.8 °C at 760 mmHg
• PKA: -1.26±0.40(Predicted)
• Flash Point: 351 °C
• PSA: 114.59000
• Density: 1.33 g/cm³
• LogP: 4.13840
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility.: Soluble in DMSO (up to 55 mg/ml) or in ethanol (up to 14 mg/ml).

Purity/Quality:

99.9% ^*data from raw suppliers

Eltrombopag ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Description: ITP is an autoimmune disease in which antiplatelet antibodies accelerate the destruction of platelets. In addition, platelet production can be impaired because the antiplatelet antibodies can also damage megakaryocytes. Although the thrombocytopenia of ITP can be severe, signs of bleeding are usually only minor. Eltrombopag is an oral, small-molecule, nonpeptide TPO-receptor agonist. It initiates TPO-receptor signaling by interacting with the transmembrane domain of the receptor, thereby inducing proliferation and differentiation of cells in the megakaryocytic lineage. Eltrombopag is the second TPO-receptor agonist to reach the market behind romiplostim (Nplate), a recombinant fusion protein launched in 2008. Both drugs are specifically indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag is supplied as the ethanolamine salt (also known as eltrombopag olamine). The most common adverse reactions associated with eltrombopag were nausea, vomiting, mennorrhagia, myalgia, paresthesia and cataracts. Eltrombopag is derived in five synthetic steps starting from 2-bromo-6-nitroanisole, via Suzuki coupling reaction with 3-carboxyphenylboronic acid to a biphenyl intermediate, followed by cleavage of the methyl ether moiety with hydrobromic acid, and reduction of the nitro group to an amino group under catalytic hydrogenation conditions. Subsequently, the amino group is diazotized with sodium nitrite and hydrochloric acid, and the diazonium intermediate is condensed with 1-(3,4-dimethylphenyl)-3-methyl-2,5-dihydro-1H-pyrazol-5-one to produce eltrombopag.
• Uses: An agonist of the Thrombopoietin (Tpo) receptor, used as treatment for thrombocytopenia. Eltrombopag (SB-497115-GR, Promacta, Revolade) is a small molecule agonist of the c-mpl (TpoR) receptor with an IC50 of 0.69 μM for the inhibition of hERG K+ channel tail current. In preclinical studies, the compound was shown to interact selectively with An agonist of the Thrombopoietin (Tpo) receptor, used as treatment for thrombocytopenia
• Clinical Use: Thrombopoetin receptor agonist:Treatment of chronic immune idiopathic thrombocytopenic purpura (ITP)Chronic hepatitis C associated thrombocytopenia (HCV)Severe aplastic anaemia
• Drug interactions: Potentially hazardous interactions with other drugs Ciclosporin: concentration of eltrombopag reduced. Statins: increased rosuvastatin concentration, may need to reduce rosuvastatin dose.